Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Joins Gene Logic’s Stable Of Pharma Partners

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott could pay Gene Logic as much as $100 million in milestones for each drug candidate that is eventually marketed, firm tells “The Pink Sheet” DAILY.

You may also be interested in...



Gene Logic Adds Merck Serono To Growing List Of Pharma Partners

Firm seeks a development partner for its internal candidate, GL1001, which has shown indications of efficacy in vivo for inflammatory bowel disease.

Gene Logic Adds Merck Serono To Growing List Of Pharma Partners

Firm seeks a development partner for its internal candidate, GL1001, which has shown indications of efficacy in vivo for inflammatory bowel disease.

Gene Logic Adds Lilly To Its Drug Rescue Roster

Company will reconsider drug candidates that were “discontinued or de-prioritized” for non-safety reasons and could even license them if Lilly opts out.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel